Covariate-adjusted posterior probabilities that gemtuzumab ozogamicin (GO) with (+) or without (−) interleukin 11 (IL-11) was associated with a lower complete remission rate than idarubicin plus cytosine arabinoside (IA)
| Assumed trial effect, posterior mean (SD) . | Posterior probability that GO with or without IL-11 was inferior to IA . | |||||
|---|---|---|---|---|---|---|
| Normal cytogenetic findings . | Cytogenetic finding of −5/−7 . | Other cytogenetic abnormalities . | ||||
| GO − IL-11 . | GO + IL-11 . | GO − IL-11 . | GO + IL-11 . | GO − IL-11 . | GO + IL-11 . | |
| 0.233 (0.629) | 0.996 | 0.631 | 1.0 | 0.980 | 0.999 | 0.868 |
| −0.233 (0.629) | 0.987 | 0.446 | 1.0 | 0.949 | 0.997 | 0.755 |
| 0.156 (0.618) | 0.995 | 0.601 | 1.0 | 0.977 | 0.999 | 0.852 |
| −0.156 (0.618) | 0.989 | 0.477 | 1.0 | 0.956 | 0.998 | 0.776 |
| Assumed trial effect, posterior mean (SD) . | Posterior probability that GO with or without IL-11 was inferior to IA . | |||||
|---|---|---|---|---|---|---|
| Normal cytogenetic findings . | Cytogenetic finding of −5/−7 . | Other cytogenetic abnormalities . | ||||
| GO − IL-11 . | GO + IL-11 . | GO − IL-11 . | GO + IL-11 . | GO − IL-11 . | GO + IL-11 . | |
| 0.233 (0.629) | 0.996 | 0.631 | 1.0 | 0.980 | 0.999 | 0.868 |
| −0.233 (0.629) | 0.987 | 0.446 | 1.0 | 0.949 | 0.997 | 0.755 |
| 0.156 (0.618) | 0.995 | 0.601 | 1.0 | 0.977 | 0.999 | 0.852 |
| −0.156 (0.618) | 0.989 | 0.477 | 1.0 | 0.956 | 0.998 | 0.776 |